Biotech Leader Sid Senroy Joins Contakt World as Board Member, Special Advisor to CVO; RegDev Engaged to Source COVID-19 Testing Kit Vendors for Integration with Smart Health RM

Sid Senroy and his firm RegDev, Inc. ("RegDev") have assisted with regulatory approval of drugs with more than $30B in annual sales
Mr. Senroy joins Contakt World's Board of Directors as special advisor to CVO Justin Beck, and as a commercial advisor for international markets
RegDev engaged to source COVID-19 testing kits for a seamless testing, tracing, case management solution via Smart Health RM - Contakt World's SaaS solution

Contakt World Technologies Corp. (CSE: HELP) (OTC: TLOOF) (FSE: B2I) (the "Company" or "Contakt World") is pleased to announce the retention of biotech and pharmaceutical leader Sid Senroy as a member of its Board of Directors, as special advisor to Chief Visionary Officer ("CVO") Justin Beck, and as commercial advisor for international markets. The leading regulatory affairs and compliance firm owned by Mr. Senroy, RegDev, was also retained by Contakt World to develop supply chains for disease testing.

Justin Beck, CVO and founder of Contakt World, commented, "we are humbled to have Mr. Senroy, an icon and visionary who has helped achieve regulatory approval for pharmaceuticals with more than $30B in annual sales, join us in several capacities. In addition to his service on our Board, I will work closely with Mr. Senroy to develop channels for our products and services, and toward innovation for Contakt World that solves challenges for humanity."

Mr. Senroy added, "I believe Contakt World is developing something special, from their team to their SaaS platform, Smart Health RM. I look forward to applying my personal experience, as well as my team at RegDev, to accelerate and realize our Company plans. The need to improve testing has never been more apparent than during the pandemic. Our success could save lives."

INTEGRATED DISEASE TESTING & SUPPLY CHAINS

Contakt World engaged RegDev to source supply from multiple COVID-19 testing kit vendors with a vision of integrated disease testing, contact tracing, case management, and case monitoring via Smart Health RM. With seamless testing kit sales and results for disease cases, customers of Contakt World will be able to isolate cases without wasted administrative steps and disparate data silos which have led to countless deaths worldwide. While the initial engagement of RegDev is centered upon COVID-19 test kits, the Company intends to use these initial vendor relationships aligned by RegDev as a springboard for other disease testing integrated with Smart Health RM.

After disease testing supply and results are integrated with Smart Health RM, Contakt World will be positioned to link testing with strain sequencing, which will help the world understand variants and the factors influencing evolution and morphology in contagions. All these steps are intended to provide public and private markets with unique capacity to address the outbreak of any disease, which Contakt World envisions as the key to successful health infrastructure. Mr. Beck added, "if we can buy and ship a package anywhere in the world in days as a society, we can find and trace disease cases successfully. We have to be bold, and we can't settle for the way things have worked. We're trying to disrupt the way we find, trace, and monitor disease cases forever."

SID SENROY

Mr. Senroy is a leader in the global biotech and pharmaceuticals industry, with an MBA from Pepperdine University. His expertise centers on helping companies pass compliance assessments, develop robust quality systems, and prepare for global health authority reviews and inspections.

As president and founder of RegDev, a global drug development consulting firm focused on regulatory compliance and processes, he has helped small to large, public and private pharmaceutical companies achieve their goals, including support of bioresearch monitoring inspections, and 30+ successful NDA / BLA Submissions / Review / Approvals leading to $30+ billion USD in annual sales from those products.

COMPENSATION AWARDS

In connection with the retention of consultants, officers, and directors - Contakt World has issued a total of 1,530,000 RSUs and 4,200,000 stock options at an exercise price of $0.58.

CORPORATE CHANGES

The Company has received the resignation of Catherine Delcin, Esq. as a Director of the Board, and the consent of Siddhartha Senroy to join the Board. The Company wishes to thank Ms. Delcin for her outstanding service to the Company. Ms. Delcin will continue as an employee of the Company.

The Company also announces the appointment of Diana Mark as Corporate Secretary, and that it has moved its registered and records office to 6204-125^th Street, Surrey, BC V3X 2E1.

Contakt World Contact
Zayn Kalyan
Interim CEO and Director
zayn@altuscapital.ca

About Contakt World

Contakt World is a technology company developing and delivering SaaS solutions for the public and private sectors. The company integrates data collection and management, communications, advertising, and IoT devices - providing customers with a scalable ecosystem that makes sense of people, place, time, and space for the emerging "phygital" (blending physical and digital) world. Contakt World is committed to improving health equity and disease management while solving sector-specific business challenges.

For more information, please visit the Company's website at www.contakt.world.

Contakt World Investor Contact
Lucas A. Zimmerman, Senior Vice President - MZ North America
Direct: 949-259-4987
contakt@mzgroup.us
www.mzgroup.us

Forward-Looking Statements

Certain information set forth in this press release contains statements that reflect "forward-looking information", as such term is defined under Canadian securities laws ("forward-looking statements"). These forward-looking statements are often identified by words such as "intends", "anticipates", "expects", "believes", "plans", "likely" or similar words. Specifically, this news release includes forward-looking statements regarding Mr. Senroy's appointment, the Company's agreement with RegDev and the Company's future business plans. The forward-looking statements reflect the Contakt World's management's expectations, estimates, or projections concerning future results or events, based on the opinions, assumptions and estimates considered reasonable by management at the date the statements are made. Although Contakt World believes that the expectations reflected in the forward-looking statements are reasonable, forward-looking statements involve risks and uncertainties and undue reliance should not be placed on forward-looking statements, as unknown or unpredictable factors could cause actual results to be materially different from those reflected in the forward-looking statements. The forward-looking statements may also be affected by risks and uncertainties in the business of Contakt World, including those described in the Company's public filings available on www.SEDAR.com. The Company undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change, except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

The Canadian Securities Exchange (CSE) has not reviewed, approved or disapproved the content of this news release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/90716

News Provided by Newsfile via QuoteMedia

Contakt World CSE:HELP Emerging Tech Investing

Sona's Cancer Therapy Triggers Abscopal Effect, Eliminating Distant Tumors In Preclinical Melanoma Study

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that a detailed biomarker analysis of the recently reported pre-clinical melanoma study conducted at Dalhousie University (the "Study") indicates that, beyond shrinking tumors on its own, Sona's Targeted Hyperthermia Therapy ("THT") also stimulates the innate immune system to target and eliminate untreated (contralateral) tumors when combined with a standard immunotherapeutic drug, IL-2. (See figure #1, below.) On the basis of efficacy data achieved in two different murine cancer models (triple negative breast cancer and malignant melanoma), the Company is now proceeding with safety and biocompatibility testing that will be required by regulating agencies to enter into human studies.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

PRINCIPAL TECHNOLOGIES ANNOUNCES CLOSING OF FIRST TRANCHE OF PRIVATE PLACEMENT

Principal Technologies Inc. (the " Company ") (TSXV: PTEC) (FSE: J07), is pleased to announce the closing of the first tranche (" Tranche 1 ") of its previously announced non-brokered private placement (the " Offering ") with one investor, MRPT Invest UG (" MRPT "), a company owned and controlled by Markus Mair . The Company issued a total of 4,000,000 units at $0.25 per unit for gross proceeds of $1,000,000 . Each unit (a " Unit ") will consist of one common share (a ' Share ") of the Company and one common share purchase warrant (a " Warrant "). Each Warrant entitles the holder to purchase one additional Share of the Company at $0.30 for a period of two (2) years from the date of closing. The Warrants are subject to a blocker term that prohibits exercise of the Warrants to the extent the holder would as a result of any exercise exceed 19.99% of then issued Shares.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Sona's Therapy Shows Significant Preclinical Efficacy in Second Cancer

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that its targeted hyperthermia therapy ("THT") demonstrated positive results in a second preclinical cancer model. Findings just presented at the 2024 STING & TLR Targeted Therapies Summit for immunotherapies in San Diego, California, show that Sona's THT achieved responses in a preclinical melanoma model equal to that which was recently reported from its triple negative breast cancer study. THT effectively treated melanoma tumors in all animals when administered on its own. Further, when THT was combined with doses of interleukin-2 ("IL-2"), a standard immunotherapy, a synergistic effect was shown whereby greater treatment response, measured by tumor volume reduction, was achieved in comparison to either approach alone.